SCHEMBL4893166

SCHEMBL4893166

Cc1cc(C)cc(COc2c(Cl)cc(C(=O)C(=O)O)cc2Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 3/20 0.45
PTPN1 P18031 3/20 0.45
PTPRF P10586 1/20 0.45
PARP10 Q53GL7 1/20 0.44
PLAU P00749 2/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 1/20 0.44
MRGPRX4 Q96LA9 3/20 0.43
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
PTPN2 P17706 1/20 0.40
POLB P06746 1/20 0.39
ALKBH1 Q13686 1/20 0.39
MEN1 O00255 1/20 0.39
NPY1R P25929 1/20 0.39
NPY2R P49146 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4895185 0.85 PTPRC (0.47) PTPRCPTPN1PTPRFPARP10PLAU
SCHEMBL4888400 0.80 GLRA1 (0.54) PTPRCPTPN1PTPRFPARP10KDM4E
SCHEMBL4896413 0.76 MRGPRX4 (0.57) PTPRCPTPN1ALDH1A1MRGPRX4ALKBH1
SCHEMBL4888397 0.75 PLAU (0.53) PLAUKDM4E
SCHEMBL4541132 0.75 THRB (0.46) PARP10KDM4EMRGPRX4FFAR1FFAR4
SCHEMBL4897119 0.75 THRA (0.56) PTPRCPTPN1PARP10KDM4EALDH1A1
SCHEMBL4525572 0.75 KDM4E (0.41) PARP10PLAUKDM4EALDH1A1MRGPRX4
SCHEMBL4891284 0.73 PLA2G2A (0.54) PLAU
SCHEMBL4929428 0.72 ALDH1A1 (0.39) PLAUKDM4EALDH1A1MRGPRX4MEN1
SCHEMBL15680256 0.72 KDM4E (0.53) PTPRCPTPN1PTPRFKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080027096-A1 Novel Pharmaceutical Compositions KARO BIO AB (SE) 2008-01-31 US disclosed
EP-1729756-A2 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2006-12-13 EP disclosed
WO-2005094810-A2 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027096-A1 Novel Pharmaceutical Compositions AR, NR5A1, CYP17A1 PTPRC 2648/4885PTPN1 1453/4885PTPRF 2912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.